Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report

Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller · 2025

Read Successful outcome of Rituximab treatment based on lymphocyte immunophenotyping in active Thyroid Eye Disease: a case report by Mirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743398.txt.

Description

Mirco Armenti and co-authors reported a case in 2025 of thyroid eye disease treated with a B-cell drug. The drug is a second-line option when steroids fail in moderate to severe active disease. The team tracked immune cells in blood, thyroid, and neck lymph nodes before and after treatment.

A man aged fifty-three had disease return eighteen months after steroid treatment. Two doses of the drug made the disease inactive, as B cells fell sharply in lymph nodes. T cell groups also shifted, likely from loss of B-cell support. Later eye surgery tissue still held B cells of other types. The authors call this the first such guided personal therapy report.

Catalog record

CREATORMirco Armenti, Sara Maioli, Chiara Riva, Nicola Currò, Giorgia Moschetti, Mario Salvi, Ilaria Muller
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12743398

Browse the full library · About the Tower of Babel